A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating ...